Stoke Therapeutics (STOK) EBT (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly EBT of -$50.0 million for Q1 2026, down 143.8% year-over-year from $114.2 million in Q1 2025, and up 19.91% quarter-over-quarter from -$62.4 million in Q4 2025.
Stoke Therapeutics (STOK) EBT (2018 - 2026) Analysis & Trends
Stoke Therapeutics' EBT history runs 9 years deep, the most recent figure standing at -$50.0 million for Q1 2026.
- In Q1 2026, EBT fell 143.8% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$175.5 million (down 471.22% YoY), while the FY2025 annual figure was -$204.3 million, down 67.55% from the prior year.
- EBT for Q1 2026 stood at -$50.0 million, up from -$62.4 million in the prior quarter.
- The five-year high for EBT was $114.2 million in Q1 2025, with the low at -$162.8 million in Q4 2023.
- The 5-year median for EBT is -$27.2 million (2023), against an average of -$36.4 million.
- Peak annual rise in EBT reached 532.84% in 2025, while the deepest fall reached 323.5% in 2025.
- Stoke Therapeutics' EBT stood at -$124.5 million in 2022, then tumbled by 30.69% to -$162.8 million in 2023, then jumped by 90.94% to -$14.7 million in 2024, then plunged by 323.5% to -$62.4 million in 2025, then increased by 19.91% to -$50.0 million in 2026.
- Business Quant data shows STOK's EBT at -$50.0 million in Q1 2026, -$62.4 million in Q4 2025, and -$39.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -61.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.62 Mn |
| Mar 31, 2026 | -50.00 Mn |
| Dec 31, 2025 | -62.44 Mn |
| Sep 30, 2025 | -39.63 Mn |
| Jun 30, 2025 | -23.48 Mn |
| Mar 31, 2025 | 114.16 Mn |
| Dec 31, 2024 | -14.74 Mn |
| Sep 30, 2024 | -26.43 Mn |
| Jun 30, 2024 | -25.70 Mn |
| Mar 31, 2024 | -26.37 Mn |
| Dec 31, 2023 | -162.77 Mn |
| Sep 30, 2023 | -27.17 Mn |
| Jun 30, 2023 | -37.09 Mn |
| Mar 31, 2023 | -24.71 Mn |
| Dec 31, 2022 | -124.55 Mn |
| Sep 30, 2022 | -29.28 Mn |
| Jun 30, 2022 | -32.19 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -90.70 Mn |
| Sep 30, 2021 | -25.27 Mn |